At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Prospective Randomized Clinical Trial of Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer
In Brief
A Phase 3 clinical trial evaluating xintilimab injection and Control for Neoadjuvant Chemoradiation Therapy and 3 related conditions. Completed, enrolled 201 participants across 1 site.
Detailed Summary
At present, there are no relevant studies or reports on the effect of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer. Studied in this paper combin neoadjuvant chemoradiation with immune therapy, carry out "Multicenter prospective randomized clinical trial of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer" in order to provide a high-level evidence-based medical evidence for ultra-low rectal cancer treatment and improve ultra-low rectal cancer diagnosis and treatment effect.
Study Details
Timeline
Interventions
neoadjuvant chemoradiation therapy +xintilimab injection 200mg/3week 4cycle
neoadjuvant chemoradiation therapy